KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
32 hedge funds and large institutions have $7.6M invested in KalVista Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 19 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
32% less funds holding
Funds holding: 47 → 32 (-15)
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
82% less capital invested
Capital invested by funds: $42.5M → $7.6M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$633K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$184K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$47.5K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$36.3K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.24M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.27M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.81M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.3M |
| 5 |
OA
Omega Advisors
New York
|
-$353K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$789 | +44 | New |
|
KALV Hedge Fund Activity: Q1 2016 in Review
32 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2016, worth a combined $7.6M — down 82% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KALV and 4 opened new positions — a net loss of 15 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was Goldman Sachs, adding an estimated $633K. The largest seller was Franklin Resources, exiting entirely with an estimated $5.24M sold.
- 32 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2016, down from 47 in Q4 2015.
- Funds reported $7.6M of KalVista Pharmaceuticals stock for Q1 2016, down 82% quarter-over-quarter.
- 4 funds opened new KalVista Pharmaceuticals positions in Q1 2016 and 19 closed out, a net change of -15 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2016 was Goldman Sachs, an estimated $633K added.
- The largest KalVista Pharmaceuticals seller in Q1 2016 was Franklin Resources, an estimated $5.24M sold.
Based on aggregated 13F filings for Q1 2016.